Probiotic Therapy (BIO-THREE) Mitigates Intestinal Microbial Imbalance and Intestinal Damage Caused by Oxaliplatin

Wang, Yuan; Xiao, Xiongxin; Yu, Xuan; Xie, Fuquan; Feng, Ping; Malik, Kamran; Wu, Jingyuan; Ye, Ze; Zhang, Peng

doi:10.1007/s12602-021-09795-3

Cited by 21 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The colony forming unit (CFU)/rat weight (g) of the administered probiotics were as follows: B. subtilis TO-A 2.5 × 10 3 , E. faecium T-110 1 × 10 4 , and C. butyricum TO-A 2.5 × 10 3 /g. Successful colonization of probiotic bacteria in the gut environment is an important factor for their function 30 . In this study, we could not confirm colonization of this probiotic in the intestine because the identification method was not disclosed by the manufacturer, but previous studies have confirmed the colonization of probiotics in the intestine 30 , 31 .…”

Section: Discussionmentioning

confidence: 99%

“…Successful colonization of probiotic bacteria in the gut environment is an important factor for their function 30 . In this study, we could not confirm colonization of this probiotic in the intestine because the identification method was not disclosed by the manufacturer, but previous studies have confirmed the colonization of probiotics in the intestine 30 , 31 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of probiotics on loperamide-induced constipation in rats

Inatomi

Honma²

2021

Sci Rep

View full text Add to dashboard Cite

The role of probiotics in mitigating constipation, gut immunity, and gut microbiota has not been well studied. We aimed to evaluate the effects of probiotics on loperamide (LP)-induced constipation in Sprague–Dawley rats. Altogether, 150 male Sprague–Dawley rats (age 8 weeks) were used in the experiments following a 12-day acclimatisation period and were randomly divided into three treatment groups (groups 1, 2, and 3). Spastic constipation was induced via oral LP administration (3 mg/kg) for 6 days, 1 h before administering each test compound in groups 1 and 2. A probiotic solution (4 mL/kg body weight) was orally administered once a day for 6 days in group 2. In group 1, a phosphate buffer solution was orally administered once a day for 6 days, 1 h after each LP administration. In group 3, a phosphate buffer solution was orally administered once a day for 6 days. In the probiotic group, faecal parameters improved; faecal n-butyric acid, acetic acid, and IgA concentrations were increased; intestinal transit time was shortened; and disturbance of intestinal microbiota was inhibited. Our findings suggest that this probiotic was useful in improving various symptoms caused by constipation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effects of probiotics on loperamide-induced constipation in rats

Inatomi

Honma²

2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Those same patients experienced fewer markers of inflammation, decreased T-cell activation, reduced intestinal permeability, increased microbial diversity, and fewer physical signs of histological damage [68 ▪▪ ]. In another study, a probiotic mixture, BIO-THREE, was reported to decrease intestinal damage following oxaliplatin-induced mucositis in mice and humans by restoring the abundance of Bacteroidetes and Prevotella [69]. A probiotic mixture including Bifidobacterium brevis DM8310, Lactobacillus acidophilus DM8302, L. casei DM8121, and Streptococcus thermophiles DM8309 prevented cisplatin-induced intestine injury in rats through anti-inflammatory and antiemetic effects [70].…”

Section: Probioticsmentioning

confidence: 98%

Nonpharmacological approaches for improving gut resilience to chemotherapy

Bullard¹,

McDonald²,

Cardaci³

et al. 2022

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of reviewMucositis of the gastrointestinal tract is a debilitating side effect of chemotherapy that negatively influences treatment tolerance and patient life quality. This review will evaluate the recent literature on nonpharmacological strategies that have the potential to improve chemotherapy-induced mucositis (CIM).Recent findingsAlternatives to pharmacological approaches have shown great promise in preventing CIM. Natural products, including curcumin, ginseng, quercetin, and patchouli all show potential in mitigating CIM. In addition, dietary patterns, such as the elemental diet, high fiber diet, and diets high in amino acids have documented benefits in preventing CIM. Perhaps the greatest advancement coming to this arena in recent years is in the field of probiotics. Indeed, research on single species as well as probiotic mixtures show potential in reducing CIM insofar as probiotics are now being suggested for treatment of CIM by governing bodies. Although behavioral interventions including psychological interventions and exercise interventions have shown promise in reducing cancer therapy-related side effects, more work in this domain is warranted and particularly in the context of CIM.SummaryAlternatives to pharmacological approaches show great potential for use in prevention and treatment of CIM and should be further developed for use in the clinic.

show abstract

“…Probiotic products have already been used as drugs for treating damage caused by chemotherapeutic drugs, such as gastrointestinal mucositis associated with the use of oxaliplatin. Here, the probiotic mixture BIO-THREE, produced by the Toa Pharmaceutical Co., Ltd. containing the bacterial strains C. butyricum , Bacillus mesentericus , and Streptococcus faecalis was used ( Yuan et al, 2022 ). It is to be expected that probiotic strains with more specific action in metabolic pathways and regulation of genes associated with tumor processes will be used as drugs in precision medicine, not only for the large market that this represents, but for the possibility of developing an effective mitigation system of different types of cancer.…”

Section: Literature Reviewmentioning

confidence: 99%

Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover

Schemczssen-Graeff

Pileggi

2022

Front. Genet.

View full text Add to dashboard Cite

Molecular biology techniques allowed access to non-culturable microorganisms, while studies using analytical chemistry, as Liquid Chromatography and Tandem Mass Spectrometry, showed the existence of a complex communication system among bacteria, signaled by quorum sensing molecules. These approaches also allowed the understanding of dysbiosis, in which imbalances in the microbiome diversity, caused by antibiotics, environmental toxins and processed foods, lead to the constitution of different diseases, as cancer. Colorectal cancer, for example, can originate by a dysbiosis configuration, which leads to biofilm formation, production of toxic metabolites, DNA damage in intestinal epithelial cells through the secretion of genotoxins, and epigenetic regulation of oncogenes. However, probiotic strains can also act in epigenetic processes, and so be use for recovering important intestinal functions and controlling dysbiosis and cancer mitigation through the metabolism of drugs used in chemotherapy, controlling the proliferation of cancer cells, improving the immune response of the host, regulation of cell differentiation and apoptosis, among others. There are still gaps in studies on the effectiveness of the use of probiotics, therefore omics and analytical chemistry are important approaches to understand the role of bacterial communication, formation of biofilms, and the effects of probiotics and microbiome on chemotherapy. The use of probiotics, prebiotics, synbiotics, and metabiotics should be considered as a complement to other more invasive and hazard therapies, such chemotherapy, surgery, and radiotherapy. The study of potential bacteria for cancer treatment, as the next-generation probiotics and Live Biotherapeutic Products, can have a controlling action in epigenetic processes, enabling the use of these bacteria for the mitigation of specific diseases through changes in the regulation of genes of microbiome and host. Thus, it is possible that a path of medicine in the times to come will be more patient-specific treatments, depending on the environmental, genetic, epigenetic and microbiome characteristics of the host.

show abstract

Probiotic Therapy (BIO-THREE) Mitigates Intestinal Microbial Imbalance and Intestinal Damage Caused by Oxaliplatin

Cited by 21 publications

References 32 publications

Effects of probiotics on loperamide-induced constipation in rats

Effects of probiotics on loperamide-induced constipation in rats

Nonpharmacological approaches for improving gut resilience to chemotherapy

Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover

Contact Info

Product

Resources

About